Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.

Author: CatleyLaurie, FabbroDoriano, GriffinJames D, Hall-MeyersElizabeth, JiangJingrui, KungAndrew L, ManleyPaul W, MorenoDaisy, PodarKlaus, RayArghya, WeisbergEllen, WrightRenee D

Paper Details 
Original Abstract of the Article :
Activating mutations in platelet-derived growth factor receptor alpha (PDGFRA) have been reported in a subset of gastrointestinal stromal tumor (GIST) patients who do not express the mutant stem cell factor receptor c-kit. The responsiveness of mutant PDGFRA-positive GIST to imatinib depends on the ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/17087936

データ提供:米国国立医学図書館(NLM)

Targeted Therapy: New Hope for GIST Patients

Gastrointestinal stromal tumors (GISTs) are a type of cancer that affects the digestive system. This research investigated the effectiveness of three tyrosine kinase inhibitors – PKC412, nilotinib, and imatinib – in treating GISTs with specific mutations in the PDGFRA gene. The study compared the effects of these drugs on two GIST-associated PDGFRA mutants, V561D and D842V, which exhibit different sensitivities to imatinib. The study found that PKC412 and nilotinib were more effective in inhibiting the growth of GIST cells with the D842V mutation, which is typically resistant to imatinib.

Personalized Medicine: Tailoring Treatment to Individual Needs

This research highlights the importance of personalized medicine, where treatment strategies are tailored to the specific genetic characteristics of a patient's tumor.

Hope for a Cure: Advances in Cancer Treatment

This research showcases the progress being made in developing targeted therapies for cancer, offering new hope for patients.

Dr.Camel's Conclusion

This research is like a treasure hunt in the vast desert of cancer research, uncovering new and effective treatments for GISTs.

Date :
  1. Date Completed 2007-01-30
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

17087936

DOI: Digital Object Identifier

NIHMS23357

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.